Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.
Maria ChaparroSandra HermidaDiana AcostaAgnès Fernández-ClotetManuel Barreiro-de AcostaÁlvaro Hernández MartínezMaite ArroyoMarta Maia Bosca-WattsM Teresa Diz-Lois PalomaresLuis MenchénJesús Martínez CadillaEduardo Leo-CarnereroCarmen Muñoz VillafrancaMónica Sierra-AusínYago González-LamaSabino RiestraPau Sendra RumbeuM José Cabello TapiaIrene García de la FiliaRaquel VicenteDaniel CeballosRamón Pajares VillarroyaPatricia Ramírez de la PiscinaMaría Dolores Martín-ArranzLaura RamosAlexandra Ruiz-CerullaTeresa de Jesús Martínez-PérezElena San Miguel AmeliviaXavier Calvet CalvoJose Maria HuguetAlma Keco-HuergaRufo H Lorente PoyatosJosé Fernando MuñozÁngel Ponferrada-DíazBeatriz SiciliaPedro Delgado-GuillenaElena Gómez DelgadoFrancisco J Rancel-MedinaHoracio Alonso-GalánBelén HerrerosMontserrat RiveroPilar VarelaFernando BermejoMarifé García SepulcreLeticia Gimeno-PitarchLilyan Kolle-CassoLucía Márquez-MosqueraPilar Martínez TiradoCynthia RamírezEva Sesé AbizandaCarmen Dueñas SadornilHipólito Fernández RosáenzAna GutiérrezRosa Eva Madrigal DomínguezÓscar Nantes CastillejoYolanda Ber NietoBelén Botella MateuSantiago Frago LarramonaPilar López SerranoJosé María Rubio MateosSandra Torrá AlsinaEduardo IyoJosé Luis Fernández ForcelledoLuis HernándezMaría Carmen Rodríguez-GrauDavid Monfort MiquelManuel Van DomselaarCarmen López RamosM Jesús Ruiz BarciaFrancisco Javier García-Alonsonull nullPublished in: Alimentary pharmacology & therapeutics (2024)
Ustekinumab durability in UC was relatively high, and treatment was effective in highly refractory patients. The safety profile was consistent with previous studies.